Last reviewed · How we verify
Dantrolene sodium for injectable suspension
Dantrolene sodium works by inhibiting calcium ion release from the sarcoplasmic reticulum, thereby reducing muscle spasticity.
Dantrolene sodium works by inhibiting calcium ion release from the sarcoplasmic reticulum, thereby reducing muscle spasticity. Used for Malignant hyperthermia, Spinal cord injury, Stroke.
At a glance
| Generic name | Dantrolene sodium for injectable suspension |
|---|---|
| Also known as | Ryanodex; EGL-4104 |
| Sponsor | Eagle Pharmaceuticals, Inc. |
| Drug class | Direct-acting muscle relaxant |
| Target | Ryanodine receptor |
| Modality | Small molecule |
| Therapeutic area | Musculoskeletal |
| Phase | Phase 2 |
Mechanism of action
This action is achieved through its ability to bind to ryanodine receptors, preventing the release of calcium ions and subsequently reducing muscle contraction. As a result, dantrolene sodium is effective in treating conditions characterized by excessive muscle spasticity.
Approved indications
- Malignant hyperthermia
- Spinal cord injury
- Stroke
- Spinal cord injury associated with autonomic dysreflexia
- Cerebral palsy
- Multiple sclerosis
- Spinal muscular atrophy
- Amyotrophic lateral sclerosis
- Muscle spasticity associated with cerebral palsy
- Muscle spasticity associated with multiple sclerosis
Common side effects
- Dizziness
- Nausea
- Headache
- Fatigue
- Muscle weakness
- Diarrhea
- Abdominal pain
- Constipation
- Dyspepsia
- Rash
Key clinical trials
- Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS) (PHASE2)
- Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS (PHASE3)
- Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: